
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934.

Date of Report: August 26, 2013
(Date of earliest event reported)

Oragenics, Inc.
(Exact name of registrant as specified in its charter)

FL
(State or other jurisdiction
of incorporation)

001-32188
(Commission
File Number)

59-3410522
(IRS Employer
Identification Number)

4902 Eisenhower Boulevard, Suite 125
Tampa, FL
(Address of principal executive offices)

33634
(Zip Code)

813-286-7900
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On August 26, 2013, Oragenics, Inc. (“Oragenics” or the “Company”) issued a press release announcing initial success in the second phase of its lantibiotic development project through its collaboration work with Intrexon Corporation. A copy of the Press Release is attached as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference.

On September 12, 2013, StreetWise Reports published an interview with Keith Markey, Ph.D., a Griffin Securities, Inc. (“Griffin”) equities analyst, which included comments about the Company. The Company has an existing advisory relationship with Griffin. Dr. Markey’s comments during the interview relating to the Company are excerpted and attached hereto as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated August 26, 2013.
99.2	Excerpt of Keith Markey’s Interview with StreetWise Reports.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 12th day of September, 2013.

ORAGENICS, INC.
(Registrant)

BY: /s/ Michael Sullivan
Michael Sullivan
Chief Financial Officer



Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project

TAMPA, FL (August 26, 2013) – Oragenics, Inc. (NYSE MKT: OGEN) announced today that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE:XON), a synthetic biology company, preliminary experiments demonstrate that a genetically-modified (GM) host can be engineered to produce improved titers of OGEN's lead compound MU1140, progressing towards the commercial production of lantibiotics, a novel-class of broad-spectrum antibiotics.

The collaboration has also uncovered two new methods of purifying its lead compound resulting in higher purity and yields of MU1140. The next step will be to use the GM host to produce analogs of MU1140 that are expected to demonstrate improved antimicrobial, chemical and pharmacological properties, with the objective of building a comprehensive antibiotic pipeline against various life-threatening indications.

“The ability to produce MU1140 by fermentation was originally thought not to be commercially feasible due to low titers and purification issues. The Oragenics-Intrexon ECC has shown that the application of specific expertise in key areas may enable a viable commercial strategy and ultimately bring these important drugs into human clinical studies,” stated Dr. John N. Bonfiglio, Chief Executive Officer of Oragenics. “Preclinical development plans are currently being designed by our R&D team, which includes well-respected experts in the area of antibiotic commercialization.” Dr. Bonfiglio further stated.

In June 2012, Oragenics and Intrexon entered into an ECC to develop and commercialize lantibiotics for the treatment of infectious diseases. The companies are pursuing a pipeline of new lantibiotics that are particularly active against a variety of Gram positive bacteria that are resistant to drugs of last resort.

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation Inc., a synthetic biology company. The collaboration will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria. Oragenics also develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in over 13 countries worldwide.

For more information about Oragenics, visit www.oragenics.com. Follow Oragenics on [Facebook](#) and [Twitter](#).

Safe Harbor Statement: *Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words*

“believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond March 31, 2014, our ability to produce sufficient quantities of MU1140, or an analog, in order to commence and conduct preclinical testing; and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Corporate Contact

Michael Sullivan
Chief Financial Officer
Oragenics, Inc
4902 Eisenhower Blvd – Suite 125
Tampa, FL 33634
Tel: 813-286-7900 x246
Direct: 813-786-6431
msullivan@oragenics.com

Investor / Media Contacts

Stephanie Carrington / Aaron Estrada
The Ruth Group
Tel: +1-646-536-7017/7028
scarrington@theruthgroup.com aestrada@theruthgroup.com

Excerpt of Keith A. Markey Interview with StreetWise Reports

TLSR: Oragenics is involved with antibiotics and probiotics. What are the newest developments there?

KM: Oragenics is working behind the scenes with Intrexon Corp., a leader in synthetic biology, to optimize the production of a natural antibiotic that bacteria use to fight each other. This particular type of antibiotic is called lantibiotic. It has a very unique molecular structure, with very novel amino acids. The collaboration has set up a production cell line and purification scheme that will be adequate for producing sufficient quantities of the lantibiotic to conduct clinical trials. That is important because lantibiotics have historically been extremely difficult, if not totally impossible, to produce in large quantities. The problem is that when you try to grow bacteria that produce a lantibiotic in culture, it kills the cells at concentrations so low that purifying the compound is very difficult to achieve.

TLSR: How are the market cap and stock price holding up for Oragenics?

KM: Oragenics has been doing reasonably well compared to some biotechnology companies. In the last six months, it has traded between \$2.80-3.50. The company has not seen a lot of news flow recently, but it is making progress. Just recently, Oragenics reported that Intrexon has created variants of the natural lantibiotic and that structure-activity studies will commence shortly.